VANNUCCHI, ALESSANDRO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.488
EU - Europa 16.462
AS - Asia 1.492
AF - Africa 24
OC - Oceania 21
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 43.498
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.416
PL - Polonia 8.008
IE - Irlanda 2.115
IT - Italia 1.850
SE - Svezia 1.713
DE - Germania 623
UA - Ucraina 587
HK - Hong Kong 498
FI - Finlandia 420
CN - Cina 401
CH - Svizzera 380
GB - Regno Unito 327
VN - Vietnam 146
TR - Turchia 133
JO - Giordania 132
FR - Francia 112
BE - Belgio 99
SG - Singapore 79
ES - Italia 74
CA - Canada 72
AT - Austria 67
RU - Federazione Russa 31
TW - Taiwan 23
AE - Emirati Arabi Uniti 20
IN - India 19
NL - Olanda 19
KR - Corea 18
AU - Australia 13
CZ - Repubblica Ceca 12
SC - Seychelles 12
MU - Mauritius 9
JP - Giappone 8
NZ - Nuova Zelanda 8
RO - Romania 7
BG - Bulgaria 5
EU - Europa 4
BR - Brasile 3
DK - Danimarca 3
ID - Indonesia 3
IR - Iran 3
CL - Cile 2
EC - Ecuador 2
EG - Egitto 2
GR - Grecia 2
RS - Serbia 2
TH - Thailandia 2
AO - Angola 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BY - Bielorussia 1
EE - Estonia 1
GE - Georgia 1
LT - Lituania 1
MY - Malesia 1
NO - Norvegia 1
PH - Filippine 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
Totale 43.498
Salva come PNG Salva come JPEG
Città #
Warsaw 7.996
Fairfield 4.741
Woodbridge 2.158
Dublin 2.110
Ashburn 2.092
Seattle 1.972
Chandler 1.845
Cambridge 1.808
Houston 1.671
Wilmington 1.577
Jacksonville 995
Altamura 817
Lawrence 790
Ann Arbor 731
Princeton 655
Boston 411
Bern 379
Beijing 296
Boardman 279
San Diego 266
Medford 248
Florence 245
Buffalo 216
Bremen 162
Dong Ket 128
Izmir 110
Brussels 98
Norwalk 87
Hillsboro 76
Falls Church 64
Barcelona 62
Phoenix 59
London 55
Andover 54
Vienna 51
Toronto 47
Milan 40
Salerno 39
Dearborn 37
Auburn Hills 31
Rome 28
Washington 23
Redwood City 22
Verona 22
Abu Dhabi 18
Old Bridge 16
Fiesole 15
Redmond 15
Los Angeles 14
Taipei 14
Seongnam 13
Sesto Fiorentino 13
Brno 12
Frankfurt Am Main 12
Laurel 12
Hefei 11
San Mateo 11
Acton 9
Catania 9
Hangzhou 9
Hanover 9
Nanjing 9
Siena 9
Chicago 8
Chiswick 8
Fuzhou 8
Guangzhou 8
Napoli 8
New Bedfont 8
Romainville 8
Bari 7
Gdansk 7
Munich 7
Ottawa 7
Prescot 7
Tappahannock 7
Castelliri 6
Cortona 6
Helsinki 6
Hounslow 6
Padova 6
Pian di Scò 6
San Jose 6
Sydney 6
Augusta 5
Cantagallo 5
Cedar Knolls 5
Fontebuona 5
Islington 5
Jinan 5
Pisa 5
Prato 5
Rignano sull'Arno 5
Saint Petersburg 5
Sofia 5
Trumbull 5
Turin 5
Villamagna 5
Wuhan 5
Auckland 4
Totale 36.048
Salva come PNG Salva come JPEG
Nome #
JAK Inhibition with Ruxolitinib versus Best Available Therapyfor Myelofibrosis 269
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 265
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 246
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 238
GROWTH INHIBITION AND DIFFERENTIATION OF HUMAN BREAST CANCER CELLS BY THE PAFR ANTAGONIST WEB-2086 237
HDAC1 controls CIP2A transcription in human colorectal cancer cells 235
Advances in understanding and management of myeloproliferative neoplasms 234
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells 234
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis:an international study. 234
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 234
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 232
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 232
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 231
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 230
A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. 230
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial 229
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives 228
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 226
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 224
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 224
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. 222
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 222
EZH2 mutational status predicts poor survival in myelofibrosis. 220
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. 220
Role of miR-34a-5p in hematopoietic progenitor cells proliferation and fate decision: Novel insights into the pathogenesis of primary myelofibrosis 219
Effect of mutation order on myeloproliferative neoplasms 216
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis 214
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 213
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 213
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis 212
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN 212
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. 212
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. 211
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis 211
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium 211
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells 210
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. 210
Chronic myeloproliferative neoplasms: a collaborative approach. 207
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: An observational, hypothesis-generating study 206
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms 205
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). 204
Cardiovascular events and intensity of treatment in polycythemia vera. 204
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia 203
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation 203
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 203
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. 201
Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms. 200
Clinical significance of genetic aberrations in secondary acute myeloid leukemia 194
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 192
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. 192
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. 184
FLT3-mediated p38-MAPK activation participates in the control ofmegakaryopoiesis in primary myelofibrosis. 182
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis 179
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk ofsplanchnic vein thrombosis. 178
Characterisation and discovery of novel miRNAs andmoRNAs in JAK2V617F mutated SET2 cells 175
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer 174
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing 172
JAK2V617F-homozigosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant clone 162
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis 145
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 143
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 140
MPN Score 134
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 130
miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6 129
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 128
The european hematology association roadmap for european hematology research: A consensus document 127
First report of FIP1L1-PDGFR alpha-positive eosinophilic granulomatosis with polyangiitis 121
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group 121
STAT1 activation in association with JAK2 exon 12 mutations 121
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 120
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 120
Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera. 114
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 113
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: A snapshot of 1144 patients in the JUMP trial 113
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 111
Circ RNAs are here to stay: A perspective on the MLL recombinome 111
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation 109
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 106
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 105
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis 104
Mutations and prognosis in primary myelofibrosis. 103
Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. 103
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 103
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. 102
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 102
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion 102
Leukocytosis and risk stratification assessment in essential thrombocythemia. 101
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 101
Treatment options for essential thrombocythemia and polycythemia vera 100
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 100
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis 100
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 99
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis 99
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 99
Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis 99
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. 99
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 99
Advances in understanding and management of polycythemia vera. 98
Insights into JAK2-V617F mutation in CML. 98
Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. 96
Totale 17.048
Salva come PNG Salva come JPEG
Categoria #
all - tutte 107.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 107.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20194.679 0 0 0 0 0 126 219 127 239 816 1.715 1.437
2019/202011.839 785 788 274 992 1.387 1.485 1.361 1.558 1.284 729 960 236
2020/20216.823 563 634 405 970 324 682 279 564 613 859 450 480
2021/20223.861 123 347 367 151 112 148 144 425 191 140 618 1.095
2022/20239.998 1.012 2.009 413 742 700 1.712 1.287 514 749 104 276 480
2023/20241.926 172 413 698 221 381 41 0 0 0 0 0 0
Totale 44.322